2018, Number 6
Next >>
salud publica mex 2018; 60 (6)
Prevention of cervical cancer in Latin America: Future challenges and opportunities
Franco EL
Language: English
References: 11
Page: 609-611
PDF size: 295.11 Kb.
Text Extraction
It was not difficult to decide in 1984 that studying
cervical cancer epidemiology should be a key priority
when I began my research work at the Sao Paulo Branch
of the Ludwig Institute for Cancer Research. At the time,
Recife (the capital of the state of Pernambuco, in the
Northeastern region of Brazil) had the sad distinction
of boasting an incidence rate of over 100 new cases of
invasive cervical cancer per 100 000 women per year. In
1982, the Brazilian Ministry of Health published a very
large tumor pathology compilation that assessed relative
frequencies of cases for all cancers sites.
REFERENCES
Carvalho MRC, Franco EL. Cancer Incidence in Recife, Brazil. In: Franco EL (ed). LICR Monograph Series in Cancer Epidemiology, Vol. 2. Sao Paulo: Ludwig Institute for Cancer Research, 1986.
Brumini R (ed). Cancer in Brazil: histopathological data. Rio de Janeiro: Ministry of Health, 1982.
Franco EL, Campos Filho N, Villa LL, Torloni H. Correlation patterns of cancer relative frequencies with some socioeconomic and demographic indicators in Brazil: an ecologic study. Int J Cancer. 1988;41(1):24-9. https:// doi.org/10.1002/ijc.2910410106
Dürst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA. 1983;80(12):3812-5. https://doi.org/10.1073/pnas.80.12.3812
Meisels A, Fortin R. Condylomatous lesions of the cervix and vagina. I. Cytologic patterns. Acta Cytol. 1976;20(6):505-9.
Torres-Ibarra L, Lazcano-Ponce E, Franco EL, Cuzick J, Hernández-Ávila M, Lorincz A, et al. Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study. Salud Publica Mex. 2016;58(2):197-210. https://doi.org/10.21149/spm.v58i2.7789
Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, et al. Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial. J Natl Cancer Inst. 2018;110(2). https://doi.org/10.1093/ jnci/djx158
Wittet S. Target: elimination of cervical cancer. PATH, 2018 [cited 2018 Sep 20]. Available from: https://www.path.org/articles/target-eliminationcervical- cancer/
Franco EL, Tsu V, Herrero R, Lazcano-Ponce E, Hildesheim A, Muñoz N, et al. Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean. Vaccine. 2008;26(suppl 11):L88-95. https://doi.org/10.1016/j.vaccine.2008.05.026
Wittet S. The Cost of Cervical Cancer Prevention in Low- and Lower- Middle-Income Countries. Cervical Cancer Action [cited 2018 Sep 20]. Available from: http://cervicalcanceraction.org/pubs/CCA_cost_modeling_ brief_2017.pdf
Franco E, Villa L, Rohan T, Ferenczy A, Petzl-Erler M, Matlashewski G. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. Rev Panam Salud Publica. 1999;6(4):223-33. https://doi.org/10.1590/S1020-49891999000900001
Full text